Qiagen

Global RNA Analysis Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 21, 2021
Biotechnology, Genetics, Health, Death, Agilent Technologies, Genomics, PCR, Genome, Gene, Industry, MicroRNA, Life Technologies Corp. v. Promega Corp., Enzyme, Illumina, Inc., RNA interference, Real-time polymerase chain reaction, Drug discovery, Transcriptome, Merck, Bio-Rad Laboratories, Eurofins Scientific, RNA, Thermo Fisher Scientific, Roche, RT, Merck Group, Mindful Scientific Inc., Forensic pathology, Danaher, Collection, Protein, Company, Danaher Corporation, COVID-19, Ribonuclease, Qiagen, Polymerase chain reaction, CD Genomics, DNA, Vaccine, 3D printing

The "Global RNA Analysis Market 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global RNA Analysis Market 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • RNA species (messenger RNA, transfer RNA, and ribosomal RNA) play an important role in the translation of genetic information from DNA to proteins.
  • This report explores the present and future market values of the RNA analysis market, particularly by type of analysis such as microarrays, polymerase chain reaction (PCR), sequencing technologies, and RNAi gene silencing.
  • Also included in the report is a discussion of the impact of COVID-19 on the market and profiles of leading companies in the RNA analysis market.

DGAP-News: BioRiver selects three innovative therapeutic and diagnostic approaches as winners of the biotech start-up competition BioRiver Boost! 2021

Retrieved on: 
Wednesday, October 6, 2021
Blood, RWTH Aachen University, Biotechnology, QIAGEN, Ministry, California Governor's Office of Economic Development, Protein, Lung, IUF, DNT, Science, Patient, Institute, Carbon, Poisoning, NRW.Bank, Economic development, Digital economy, CEO, Industry, Death, Company, Environmental medicine, Life, Technology, Qiagen, Pancreas, Organization, Digitization, List of life sciences, Energy, City, Gene silencing, Miltenyi Biotec, Association, Medical device, Fine chemical, Pharmaceutical industry, Motor vehicle, Fuel oil

BioRiver selects three innovative therapeutic and diagnostic approaches as winners of the biotech start-up competition BioRiver Boost!

Key Points: 
  • BioRiver selects three innovative therapeutic and diagnostic approaches as winners of the biotech start-up competition BioRiver Boost!
  • BioRiver selects three innovative therapeutic and diagnostic approaches as winners of the biotech start-up competition BioRiver Boost!
  • Oktober 2021: For the eighth time in a row the annual start-up competition for life science and biotech founders, BioRiver Boost!, honored the best start-up companies in the industry on October 1, 2021.
  • Since 2014, the industry association BioRiver organizes BioRiver Boost!, the competition for life science founders.

Global Lateral Flow Assays Industry Assessment 2021-2028 | $8.51 Billion Opportunity Assessment by Product, Application, Technique, End-use and Region - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 5, 2021
Medical Devices, Medical Supplies, Infectious Diseases, Biotechnology, Other Health, AIDS, Health, Pharmaceutical, General Health, Adoption, Infection, President's Emergency Plan for AIDS Relief, National Institutes of Health, USD, Pressure, Diagnosis, Application, Smartphone, CAGR, Overalls, PEPFAR, Patient, Kits, DiaSorin, POC, Prevalence, Reading, HIV/AIDS, Human services, COVID-19, Technology, National Institute, U.S. Department of Defense Strategy for Operating in Cyberspace, Qiagen, Research, Lateral flow test, IUL, NIH, Incidence, HIV, Government, AIDS, Medical device, Video game console, Pharmaceutical industry

The global lateral flow assays market is expected to reach USD 8.51 billion by 2028.

Key Points: 
  • The global lateral flow assays market is expected to reach USD 8.51 billion by 2028.
  • Additionally, in March 2021, IUL SA, a Spain-based lateral flow products manufacturer, introduced its new lateral flow reader, iPeak+.
  • In addition, a rise in mergers and collaborations by market players is anticipated to facilitate access to novel lateral flow technologies.
  • The outbreak of COVID-19 has created significant demand for lateral flow assays for conducting mass testing in the U.S. and European countries.

Global Liquid Biopsy Market Outlook Report 2021-2028 - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 23, 2021
Science, Health, Oncology, Other Science, Research, USD, Illumina, Inc., IARC, Helmy Eltoukhy, CAGR, Qiagen, Thermo Fisher Scientific, International Agency for Research on Cancer, Investment, Organic, Government, Medical imaging

The "Global Liquid Biopsy Market Outlook 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Liquid Biopsy Market Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
  • The global liquid biopsy market attained revenue of close to USD 3160 Million in 2019 and is estimated to garner over USD 25800 Million in 2028.
  • The global liquid biopsy market is anticipated to grow with a CAGR of 30.7% during the forecast period, i.e., 2020-2028.
  • Some of the key players in the global liquid biopsy market that are mentioned in our report are Qiagen, F. Hoffmann-La Roche Ltd, Bio-Rad Laboratories, Inc., Illumina, Inc., Inivata Limited, Agena Bioscience, Inc., Thermo Fisher Scientific, Guardant Health, Inc. and others.

$8.4 Bn CRISPR Markets - Global Forecasts from 2021 to 2026: Escalating R&D to Provide Opportunities Market Players - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 21, 2021
Biotechnology, Genetics, Health, CRISPR, CRISPR Therapeutics, Biotechnology, Shorthand, Therapy, Gene editing, Deletion, National Center for Biotechnology Information, Anti-transglutaminase antibodies, Collection, Genome, CAGR, DNA, Amyotrophic lateral sclerosis, Cancer, Patient, Global Alliance for Genomics and Health, Lists of diseases, Library, GA4GH, Agriculture, USDA, Risk, Plasmid, Genomics, Brassica, Technology, PerkinElmer, Global Alliance, Genetic engineering, ALS, Qiagen, Friedreich's ataxia, Research, Haemophilia, Birth, Investment, Industry, Pharmaceutical industry, Vaccine

The global CRISPR market is a growing with major investments from developed countries.

Key Points: 
  • The global CRISPR market is a growing with major investments from developed countries.
  • The growing need for drug research, the risk of congenital abnormalities, and late pregnancies resulting in birth problems are key factors driving the CRISPR market forward.
  • The escalating geriatric population, Changes in lifestyles, and investment in cutting-edge research technologies are also augmenting the market size.
  • A lot of research and development happening in the market is anticipated to boost the opportunities through the inclining market trends.

The Worldwide Companion Diagnostics Industry is Expected to Reach $10.7 Billion by 2026

Retrieved on: 
Thursday, September 16, 2021
Qiagen, Mayo Collaborative Services v. Prometheus Laboratories, Inc., PCR, SRL Diagnostics, FDA, Technology, CAGR, Immunohistochemistry, NGS, Software, Thermo Fisher Scientific, IHC, Industry, In situ hybridization, Growth, Polymerase chain reaction, ISH, Cdx, Stanford University v. Roche Molecular Systems, Inc., Medical device, Pet, Pharmaceutical industry, Fine chemical

DUBLIN, Sept. 16, 2021 /PRNewswire/ -- The "Companion Diagnostics: Technologies and Global Market 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Sept. 16, 2021 /PRNewswire/ -- The "Companion Diagnostics: Technologies and Global Market 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global market for companion diagnostics (CDx) is estimated to grow from $5.4 billion in 2021 to reach $10.7 billion by 2026, at a compound annual growth rate (CAGR) of 14.6% during the forecast period of 2021-2026.
  • The global market for NGS-CDx (next-generation sequencing) is estimated to grow from $1.3 billion in 2021 to reach $3.3 billion by 2026, at a CAGR of 20.9% during the forecast period of 2021-2026.
  • This report provides a comprehensive analysis of the CDx market in the global context, including market forecasts and sales through 2026.

Why New Covid-19 Test Supplies Will Be Needed Soon in Wake of US President's New OSHA Mandates

Retrieved on: 
Tuesday, September 14, 2021
Workplace, Qiagen, Food and Drug Administration, Food, DTH, School, Reuters, Amazon, Government, US Foods, Heel, CVS Pharmacy, FDA, Vaccination, ID, CEO, Quest, DGX, Immunity, Genetic testing, SARS, Projection, QGEN, WuXi Biologics, White House, GLP, IND, NYSE, News, Occupational Safety and Health Administration, CSE, Severe acute respiratory syndrome coronavirus 2, NASDAQ, COO, POC, CVS, Rite Aid, COVID-19, OSHA, Occupational safety and health, Pharmacy, Abbott Laboratories, PCR, Partnership, Wuxi, Human, OTC, Quest Diagnostics, Abbott, White, COVID-19 policy of the Joe Biden administration, Method, Vaccine, Fine chemical, Pharmaceutical industry

For many workplaces, this could mean a drastic increase in demand for testing equipment, against a supply that's already under stress and encountering major shortages .

Key Points: 
  • For many workplaces, this could mean a drastic increase in demand for testing equipment, against a supply that's already under stress and encountering major shortages .
  • Data for this form of testing suggests it may even be more accurate than current methods, by measuring the immune system's active infection response.
  • "We strongly support all initiatives aiming to increase vaccination rates especially at the workplace," Qiagen told Reuters in an email.
  • To support the drive, the White House said it will spend nearly $2 billion on 280 million rapid COVID-19 tests.

Why New Covid-19 Test Supplies Will Be Needed Soon in Wake of US President's New OSHA Mandates

Retrieved on: 
Tuesday, September 14, 2021
Workplace, Qiagen, Food and Drug Administration, Food, DTH, School, Reuters, Amazon, Government, US Foods, Heel, CVS Pharmacy, FDA, Vaccination, ID, CEO, Quest, DGX, Immunity, Genetic testing, SARS, Projection, QGEN, WuXi Biologics, White House, GLP, IND, NYSE, News, Occupational Safety and Health Administration, CSE, Severe acute respiratory syndrome coronavirus 2, NASDAQ, COO, POC, CVS, Rite Aid, COVID-19, OSHA, Occupational safety and health, Pharmacy, Abbott Laboratories, PCR, Partnership, Wuxi, Human, OTC, Quest Diagnostics, Abbott, White, COVID-19 policy of the Joe Biden administration, Method, Vaccine, Fine chemical, Pharmaceutical industry

VANCOUVER, BC, Sept. 14, 2021 /PRNewswire/ -- USA News Group  -  More than 80 million workers in the United States are now facing a new vaccine/testing mandate being pushed by the Biden Administration through the Occupational Safety and Health Administration (OSHA) on employers with +100 employees. For many workplaces, this could mean a drastic increase in demand for testing equipment, against a supply that's already under stress and encountering major shortages. In order to meet this coming need, several new developments in testing, immunity enhancement and other biotechnologies are in progress including advancements coming from BioVaxys Technology Corp. (CSE:BIOV) (OTCQB:BVAXF), Quest Diagnostics Incorporated (NYSE:DGX), Quidel Corporation (NASDAQ:QDEL), Qiagen N.V. (NYSE:QGEN) and Abbott Laboratories (NYSE:ABT).

Key Points: 
  • For many workplaces, this could mean a drastic increase in demand for testing equipment, against a supply that's already under stress and encountering major shortages .
  • Data for this form of testing suggests it may even be more accurate than current methods, by measuring the immune system's active infection response.
  • "We strongly support all initiatives aiming to increase vaccination rates especially at the workplace," Qiagen told Reuters in an email.
  • To support the drive, the White House said it will spend nearly $2 billion on 280 million rapid COVID-19 tests.

Alzheon Appoints Adem Albayrak as Head of Operations and Earvin Liang, PhD, as Vice President of Clinical Development

Retrieved on: 
Monday, September 13, 2021
Research, Mental Health, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Genotype, Pathology, Qiagen, Whole genome sequencing, Patient, National Institute on Aging, Head, Research, Drug, Ageing, Biology, Biomarker, Neurotoxicity, Data visualization, University of Massachusetts Medical School, MD, Amyloid, Organization, Computer science, Cognition, APOE4, Acquisition, National Institute, Cancer, Alzheimer's disease, Leadership, Fast Track, Precision medicine, AD, Food, Therapy, Dementia, Semper Fidelis (march), Down syndrome, University, Technology, Safety, Senior, Brain, Dana–Farber Cancer Institute, Medical school, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Harvard Business School, Doctor of Philosophy, Neurodegeneration, Genomics, Risk, Clinical trial, Industry, Taipei Medical University, Transition, BIOBASE, Pharmaceutical industry, Medical imaging, ALZ-801, Alzheon, ALZ-801, ALZHEON

Mr. Albayrak brings more than a decade of precision medicine experience in both biopharma and academic medical centers to drive execution of Alzheons business and clinical programs.

Key Points: 
  • Mr. Albayrak brings more than a decade of precision medicine experience in both biopharma and academic medical centers to drive execution of Alzheons business and clinical programs.
  • Most recently, Mr. Albayrak served as the Senior Vice President for Technology in Health Catalysts emerging Life Sciences Business, where he led development of new products and analytical capabilities.
  • Subsequently, he led product development of pharmacogenomics products at BIOBASE, before its acquisition by Qiagen.
  • While at Dana-Farber Cancer Institute, Mr. Albayrak oversaw its precision medicine activities, enabling research, clinical interpretation, and clinical trial matching of the hospitals genomic sequencing program, Profile.

Worldwide Companion Diagnostics Market to 2026 to be Driven by Significant Partnerships and Collaborations for Development

Retrieved on: 
Monday, September 6, 2021
Companies, Life sciences, Industry economics), Medical tests, Medical software, Qiagen, Molecular diagnostics, Thermo Fisher Scientific, Abbott Laboratories, Agilent Technologies

The global companion diagnostics market is primarily driven by significant partnerships and collaborations for companion diagnostics test development.

Key Points: 
  • The global companion diagnostics market is primarily driven by significant partnerships and collaborations for companion diagnostics test development.
  • In addition, improvements in regulatory guidelines and the growing need for targeted therapies are also driving the global companion diagnostics market.
  • Increasing incidences of cancer has driven the adoption of companion diagnostics for developing drugs in cancer treatment.
  • Oncology is the leading segment in terms of revenue in global companion diagnostics market with around 82.72% market share.